Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study
Albree Tower‐Rader, Ahmad Munir Masri, Michael E. Nassif, T Abraham et autres
2 citationsEuropean Heart Journal
Albree Tower‐Rader
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
115Publications signalées
1595Citations signalées
6Affiliations récentes
Institutions déclarées
Domaines associés
Cardiomyopathy and Myosin StudiesCardiovascular Function and Risk FactorsCardiac Valve Diseases and TreatmentsCardiac Structural Anomalies and RepairCardiovascular Effects of Exercise
Publications récentes
Abstract 4341860: Machine Learning Model Outperforms Conventional Score to Distinguish Transthyretin Amyloid Cardiomyopathy from Other Cardiac Conditions that Cause Left Ventricular Hypertrophy
Midori Nagai, Keitaro Akita, Michael A. Fifer, Albree Tower‐Rader et autres
0 citationsCirculation
Efficacy and safety of long-term treatment with aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy: results from FOREST-HCM
Albree Tower‐Rader, A Masri, M E Nassif, T Abraham et autres
0 citationsEuropean Heart Journal
Endothelial Cell‐Related Proteins in Plasma Predict Major Adverse Cardiovascular Events and Worsening Heart Failure in Patients With Hypertrophic Cardiomyopathy
Keitaro Akita, Michael A. Fifer, Albree Tower‐Rader, Mathew S. Maurer et autres
2 citationsJournal of the American Heart Association
TCT-396 Extracellular Vesicle-to-Non-Vesicle Troponin Ratio Distinguishes Myocardial Infarction From Chronic or Physiologic Troponin Elevations
Michail Spanos, Priyanka Gokulnath, Aarush Singh, Christopher Azzam et autres
0 citationsJournal of the American College of Cardiology
Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM
Ahmad Masri, Mark V. Sherrid, Lubna Choudhury, Pablo García‐Pavía et autres
3 citationsJournal of Cardiac Failure
Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for Up to 128 Weeks
Milind Y. Desai, Yuichiro Okushi, Kathy Wolski, Jeffrey B. Geske et autres
9 citationsJACC. Cardiovascular imaging
Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy
Milind Y. Desai, Yuichiro Okushi, Shada Jadam, Iacopo Olivotto et autres
15 citationsJournal of the American College of Cardiology
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy
Sara Saberi, Theodore P. Abraham, Lubna Choudhury, Roberto Barriales‐Villa et autres
23 citationsJACC Heart Failure
Correction to: Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results from VALOR-HCM
Milind Y. Desai, Kathy Wolski, Anjali Owens, Jeffrey B. Geske et autres
4 citationsCirculation
Cardiopulmonary exercise testing parameters in healthy athletes vs. equally fit individuals with hypertrophic cardiomyopathy
Clíodhna McHugh, Sarah Gustus, Bradley J. Petek, Mark Schoenike et autres
7 citationsEuropean Journal of Preventive Cardiology
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Ahmad Masri, Martin S. Maron, Theodore P. Abraham, Michael E. Nassif et autres
2 citationsJACC Heart Failure
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.